Advances in Natural Products and Antibody Drugs for SLE: New Therapeutic Ideas

Overview

Journal Front Pharmacol

Date 2023 Jul 26

PMID 37492083

Authors

Yibing Han

Lingwei Liu

Bo Zang

Ruiwen Liang

Xinyue Zhao

Bin Liu

Affiliations

Soon will be listed here.

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune systemic disease with a wide range of clinical symptoms, complex development processes, and uncertain prognosis. The clinical treatment of SLE is mainly based on hormones and immunosuppressants. Research on novel therapy strategies for SLE has flourished in recent years, especially the emergence of new targeted drugs and natural products that can modulate related symptoms. This review discusses the current experience including B-cell targeted drugs (belimumab, tabalumab, blisibimod, atacicept, rituximab, ofatumumab, ocrelizumab, obexelimab, and epratuzumab), T-cell targeted drugs (abatacept, dapirolizumab, and inhibitor of syk and CaMKIV), cytokines targeted drugs (anifrolumab and sifalimumab), and natural products (curcumin, oleuropein, punicalagin, sulforaphane, icariin, apigenin, and resveratrol). The aim of this paper is to combine the existing and models and clinical research results to summarize the efficacy and mechanism of natural drugs and targeted drugs in SLE for the reference and consideration of researchers.

Citing Articles

The Role of Antioxidant Transcription Factor Nrf2 and Its Activating Compounds in Systemic Lupus Erythematosus.

Liu L, de Leeuw K, Goor H, Westra J Antioxidants (Basel). 2024; 13(10).

PMID: 39456477 PMC: 11504041. DOI: 10.3390/antiox13101224.

Early human migration determines the risk of being attacked by wolves: ethnic gene diversity on the development of systemic lupus erythematosus.

Bang S, Shim S J Rheum Dis. 2024; 31(4):200-211.

PMID: 39355544 PMC: 11439634. DOI: 10.4078/jrd.2024.0051.

References

Fava A, Petri M . Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2018; 96:1-13. PMC: 6310637. DOI: 10.1016/j.jaut.2018.11.001. View

Durcan L, ODwyer T, Petri M . Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019; 393(10188):2332-2343. DOI: 10.1016/S0140-6736(19)30237-5. View

Almaani S, Meara A, Rovin B . Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2016; 12(5):825-835. PMC: 5477208. DOI: 10.2215/CJN.05780616. View

Ichinose K, Juang Y, Crispin J, Kis-Toth K, Tsokos G . Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 2010; 63(2):523-9. PMC: 3030625. DOI: 10.1002/art.30085. View

Bag-Ozbek A, Hui-Yuen J . Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021; 17:39-54. PMC: 7814238. DOI: 10.2147/TCRM.S252592. View

Herrada A, Escobedo N, Iruretagoyena M, Valenzuela R, Burgos P, Cuitino L . Innate Immune Cells' Contribution to Systemic Lupus Erythematosus. Front Immunol. 2019; 10:772. PMC: 6476281. DOI: 10.3389/fimmu.2019.00772. View

Leandro M, Cambridge G, Edwards J, Ehrenstein M, Isenberg D . B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005; 44(12):1542-5. DOI: 10.1093/rheumatology/kei080. View

Sasaki H, Nagura K, Ishino M, Tobioka H, Kotani K, Sasaki T . Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem. 1995; 270(36):21206-19. DOI: 10.1074/jbc.270.36.21206. View

Grzanna R, Lindmark L, Frondoza C . Ginger--an herbal medicinal product with broad anti-inflammatory actions. J Med Food. 2005; 8(2):125-32. DOI: 10.1089/jmf.2005.8.125. View

10.

Merrill J, Wallace D, Wax S, Kao A, Fraser P, Chang P . Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2017; 70(2):266-276. PMC: 6099253. DOI: 10.1002/art.40360. View

11.

Apostolopoulos D, Morand E . It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2016; 56(suppl_1):i114-i122. DOI: 10.1093/rheumatology/kew406. View

12.

Ryu S, Choi H, Yoon K, Lee O, Kim K, Lee B . Oleuropein suppresses LPS-induced inflammatory responses in RAW 264.7 cell and zebrafish. J Agric Food Chem. 2015; 63(7):2098-105. DOI: 10.1021/jf505894b. View

13.

Stohl W, Merrill J, Looney R, Buyon J, Wallace D, Weisman M . Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015; 17:215. PMC: 4545922. DOI: 10.1186/s13075-015-0741-z. View

14.

Gottenberg J, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A . Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2004; 64(6):913-20. PMC: 1755517. DOI: 10.1136/ard.2004.029694. View

15.

Comte D, Karampetsou M, Tsokos G . T cells as a therapeutic target in SLE. Lupus. 2015; 24(4-5):351-63. PMC: 4372812. DOI: 10.1177/0961203314556139. View

16.

Isenberg D, Petri M, Kalunian K, Tanaka Y, Urowitz M, Hoffman R . Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2015; 75(2):323-31. DOI: 10.1136/annrheumdis-2015-207653. View

17.

Pannu N, Bhatnagar A . Combinatorial therapeutic effect of resveratrol and piperine on murine model of systemic lupus erythematosus. Inflammopharmacology. 2019; 28(2):401-424. DOI: 10.1007/s10787-019-00662-w. View

18.

Dent E, Taylor E, Turbeville H, Ryan M . Curcumin attenuates autoimmunity and renal injury in an experimental model of systemic lupus erythematosus. Physiol Rep. 2020; 8(13):e14501. PMC: 7354090. DOI: 10.14814/phy2.14501. View

19.

Merrill J, van Vollenhoven R, Buyon J, Furie R, Stohl W, Morgan-Cox M . Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind,.... Ann Rheum Dis. 2015; 75(2):332-40. DOI: 10.1136/annrheumdis-2015-207654. View

20.

Krishnan S, Juang Y, Chowdhury B, Magilavy A, Fisher C, Nguyen H . Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol. 2008; 181(11):8145-52. PMC: 2586973. DOI: 10.4049/jimmunol.181.11.8145. View